Dyax Corp. Announces Participation in Upcoming Investor Events
- Deutsche Bank (DB) 38th Annual db Access Health Care Conference on Wednesday, May 29 in Boston, Massachusetts. George Migausky, Executive Vice President and Chief Financial Officer, will speak at 4:10 p.m. ET.
- Jefferies 2013 Global Healthcare Conference on Monday, June 3 in New York City, New York. Gustav Christensen, President and Chief Executive Officer, will speak at 10:30 a.m. ET.
- Wells Fargo Securities Research & Economics 2013 Healthcare Conference on Tuesday, June 18 in Boston, Massachusetts. Mr. Christensen will speak at 2:40 p.m. ET.
Each presentation will be webcast live and may be accessed by visiting the Investor Relations section of the Companys website at www.dyax.com. The webcasts will be available on the Dyax website for a limited period of time following the conferences.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Companys key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.
The Company is developing products to expand its angioedema portfolio, including a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE and biomarker assays to identify plasma kallikrein-mediated disorders.
KALBITOR and DX-2930 were identified using Dyaxs patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 revenue generating product candidates in various stages of clinical development, including three in Phase 3 trials.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect future performance include the risks that: KALBITOR and/or DX-2930 may face competition from other products that are developed and/or marketed to treat HAE; KALBITOR and/or DX-2930 may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR and DX-2930; and other risk factors described or referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director, Investor Relations and Corporate Communications
Source: Dyax Corp.Copyright Business Wire 2013